Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDIAZ, Ana Claudia Marques Barbosa
dc.contributor.authorWITKIN, Steven Sol
dc.contributor.authorALMEIDA-NETO, Cesar de
dc.contributor.authorMENDRONE-JUNIOR, Alfredo
dc.contributor.authorROCHA, Vanderson
dc.contributor.authorCOSTA, Silvia Figueiredo
dc.contributor.authorRAMOS, Jessica Fernandes
dc.contributor.authorMENDES-CORREA, Maria Cassia
dc.date.accessioned2024-04-05T19:29:02Z
dc.date.available2024-04-05T19:29:02Z
dc.date.issued2024
dc.description.abstractHepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.identifier.citationREVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.66, article ID e11, 8p, 2024
dc.identifier.doi10.1590/S1678-9946202466011
dc.identifier.eissn1678-9946
dc.identifier.issn0036-4665
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58796
dc.language.isoeng
dc.publisherINST MEDICINA TROPICAL SAO PAULOeng
dc.relation.ispartofRevista do Instituto de Medicina Tropical de Sao Paulo
dc.rightsopenAccesseng
dc.rights.holderCopyright INST MEDICINA TROPICAL SAO PAULOeng
dc.subjectHepatitis C. Hematopoietic stem cell transplantationeng
dc.subjectPrevalenceeng
dc.subjectClinical outcome.eng
dc.subject.otherbone-marrow-transplantationeng
dc.subject.otherrisk-factorseng
dc.subject.otherblood-donorseng
dc.subject.otherb-viruseng
dc.subject.otherserologic markerseng
dc.subject.otherresidual riskeng
dc.subject.otherhcveng
dc.subject.otherrecipientseng
dc.subject.otherimpacteng
dc.subject.othertransmissioneng
dc.subject.wosInfectious Diseaseseng
dc.subject.wosParasitologyeng
dc.subject.wosTropical Medicineeng
dc.titlePrevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantationeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalRAMOS, Jessica Fernandes:Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcANA CLAUDIA MARQUES BARBOSA DIAZ
hcfmusp.contributor.author-fmusphcSTEVEN SOL WITKIN
hcfmusp.contributor.author-fmusphcCESAR DE ALMEIDA NETO
hcfmusp.contributor.author-fmusphcALFREDO MENDRONE JUNIOR
hcfmusp.contributor.author-fmusphcVANDERSON GERALDO ROCHA
hcfmusp.contributor.author-fmusphcSILVIA FIGUEIREDO COSTA
hcfmusp.contributor.author-fmusphcMARIA CASSIA JACINTHO MENDES CORREA
hcfmusp.description.articlenumbere11
hcfmusp.description.volume66
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1168589041
hcfmusp.origem.pubmed38324877
hcfmusp.origem.scopus2-s2.0-85184723181
hcfmusp.origem.wosWOS:001160463600001
hcfmusp.publisher.citySAO PAULOeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceAbdelbary H, 2020, J EGYPT NATL CANCER, V32, DOI 10.1186/s43046-020-0020-1eng
hcfmusp.relation.referenceArai Y, 2016, BONE MARROW TRANSPL, V51, P96, DOI 10.1038/bmt.2015.205eng
hcfmusp.relation.referenceBenzaken AS, 2019, BRAZ J INFECT DIS, V23, P182eng
hcfmusp.relation.referenceBorchardt RA, 2014, WORLD J GASTROENTERO, V20, P2771, DOI 10.3748/wjg.v20.i11.2771eng
hcfmusp.relation.referenceBrasil. Agencia Nacional de Vigilancia Sanitaria, Hemovigilancia no Brasil: relatorio consolidado 2007-2015eng
hcfmusp.relation.referenceBrasil. Ministerio da Saude, 2021, Bol Epidemiol, P1eng
hcfmusp.relation.referenceCacoub P, 2014, DIGEST LIVER DIS, V46, pS165, DOI 10.1016/j.dld.2014.10.005eng
hcfmusp.relation.referenceCunningham HE, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13091eng
hcfmusp.relation.referencede Almeida-Neto C, 2013, TRANSFUSION, V53, P827, DOI 10.1111/j.1537-2995.2012.03840.xeng
hcfmusp.relation.referencede Latour RP, 2008, J HEPATOL, V48, P1008, DOI 10.1016/j.jhep.2008.03.003eng
hcfmusp.relation.referencede Latour RP, 2004, BLOOD, V103, P1618, DOI 10.1182/blood-2003-06-2145eng
hcfmusp.relation.referenceEl-Sayed MH, 2004, EUR J GASTROEN HEPAT, V16, P1347, DOI 10.1097/00042737-200412000-00019eng
hcfmusp.relation.referenceFrancisci D, 2006, HAEMATOL-HEMATOL J, V91, P980eng
hcfmusp.relation.referenceHamaguchi M, 2002, INT J HEMATOL, V75, P324, DOI 10.1007/BF02982051eng
hcfmusp.relation.referenceIvantes CAP, 2004, BONE MARROW TRANSPL, V33, P1181, DOI 10.1038/sj.bmt.1704519eng
hcfmusp.relation.referenceKLINGEMANN HG, 1991, BLOOD, V78, P3306eng
hcfmusp.relation.referenceKyvernitakis A, 2016, BIOL BLOOD MARROW TR, V22, P717, DOI 10.1016/j.bbmt.2015.12.010eng
hcfmusp.relation.referenceLevi JE, 2017, TRANSFUSION MED, V27, P286, DOI 10.1111/tme.12427eng
hcfmusp.relation.referenceLjungman P, 2012, BONE MARROW TRANSPL, V47, P1217, DOI 10.1038/bmt.2011.238eng
hcfmusp.relation.referenceLocasciulli A, 2003, BONE MARROW TRANSPL, V31, P295, DOI 10.1038/sj.bmt.1703826eng
hcfmusp.relation.referenceLocasciulli A, 1999, TRANSPLANTATION, V68, P1486, DOI 10.1097/00007890-199911270-00010eng
hcfmusp.relation.referenceMendes-Oliveira F, 2015, TRANSFUS APHER SCI, V53, P238, DOI 10.1016/j.transci.2015.05.003eng
hcfmusp.relation.referenceMonich AG, 2017, TRANSFUS APHER SCI, V56, P130, DOI 10.1016/j.transci.2016.10.007eng
hcfmusp.relation.referenceVieira PCM, 2017, TRANSFUSION, V57, P1968, DOI 10.1111/trf.14146eng
hcfmusp.relation.referenceMusto P, 2002, CLIN LYMPHOMA, V3, P150, DOI 10.3816/CLM.2002.n.021eng
hcfmusp.relation.referenceNakasone H, 2013, AM J HEMATOL, V88, P477, DOI 10.1002/ajh.23436eng
hcfmusp.relation.referenceOliver NT, 2017, BONE MARROW TRANSPL, V52, P138, DOI 10.1038/bmt.2016.196eng
hcfmusp.relation.referenceOnodera K, 2021, J INFECT CHEMOTHER, V27, P1230, DOI 10.1016/j.jiac.2021.02.002eng
hcfmusp.relation.referencePessoni LL, 2019, HEMATOL TRANSF CELL, V41, P310, DOI 10.1016/j.htct.2019.03.009eng
hcfmusp.relation.referencePiñana JL, 2016, TRANSPL INFECT DIS, V18, P89, DOI 10.1111/tid.12474eng
hcfmusp.relation.referenceRamos CA, 2009, HAEMATOL-HEMATOL J, V94, P249, DOI 10.3324/haematol.13756eng
hcfmusp.relation.referenceRauwolf K, 2019, J VIRAL HEPATITIS, V26, P454, DOI 10.1111/jvh.13046eng
hcfmusp.relation.referenceShamsi TS, 2008, BONE MARROW TRANSPL, V42, pS114, DOI 10.1038/bmt.2008.137eng
hcfmusp.relation.referenceSilva Sônia Mara Nunes da, 2016, Rev. Bras. Hematol. Hemoter., V38, P206, DOI 10.1016/j.bjhh.2016.05.005eng
hcfmusp.relation.referenceStrasser SI, 1999, HEPATOLOGY, V29, P1893, DOI 10.1002/hep.510290609eng
hcfmusp.relation.referenceTomás JF, 2000, BONE MARROW TRANSPL, V26, P649, DOI 10.1038/sj.bmt.1702532eng
hcfmusp.relation.referenceTorres HA, 2015, BIOL BLOOD MARROW TR, V21, P1870, DOI 10.1016/j.bbmt.2015.07.033eng
hcfmusp.relation.referenceUnited States of America. Department of Health and Human Services. National Institutes of Health. National Institute of Allergy and Infectious Diseases. Division of AIDS, 2017, Table for grading the severity of adult and pediatric adverse eventseng
hcfmusp.relation.referenceWorld Health Organization (WHO), Hepatitis Ceng
hcfmusp.relation.referenceYakushijin K, 2016, BONE MARROW TRANSPL, V51, P403, DOI 10.1038/bmt.2015.283eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationced5c9c6-ac78-4f42-a42d-3f5531f6dcea
relation.isAuthorOfPublication1b8dfcc8-906a-4df2-91c2-3c7c7b08f46d
relation.isAuthorOfPublication97cdde77-5f90-4f99-a5eb-9275a5d55e78
relation.isAuthorOfPublication4a7139e3-a8d0-4218-8aeb-fdd2698cbdd0
relation.isAuthorOfPublicationde2f3a4b-2ec5-4412-a066-2afdd291efc7
relation.isAuthorOfPublicationd786dd7f-b93c-49e1-8561-c635a58c378f
relation.isAuthorOfPublication4ec4044d-75d1-4d30-8176-efd04b22c8d6
relation.isAuthorOfPublication.latestForDiscoveryced5c9c6-ac78-4f42-a42d-3f5531f6dcea
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM